<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002312</url>
  </required_header>
  <id_info>
    <org_study_id>CMO2009/322</org_study_id>
    <nct_id>NCT02002312</nct_id>
  </id_info>
  <brief_title>Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer</brief_title>
  <official_title>Phase II Study Of Lutetium-177 Labeled Chimeric Monoclonal Antibody Girentuximab (177Lu-DOTA-girentuximab) in Patients With Advanced Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of multiple doses Lutetium-177-DOTA-girentuximab in patients with&#xD;
      advanced clear cell renal cell carcinoma using RECIST criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II study using Lu-177-DOTA-girentuximab for treatment of patients with&#xD;
      advanced clear cell renal cell carcinoma. The trial requires 14 patients. CT scans will be&#xD;
      carried out at baseline and after 12 weeks, for response assessment using RECIST criteria.&#xD;
&#xD;
      Patients will initially receive 5 mCi/10 mg Indium-111-DOTA-girentuximab antibody (an imaging&#xD;
      dose preceeding Lu-177-girentuximab treatment). Whole body and blood measurements of&#xD;
      radioactivity will be obtained on at least three occasions for one week to determine&#xD;
      targeting and dosimetry. Only if at least one known and evaluable metastatic lesion is&#xD;
      visualized with In-111-DOTA-girentuximab, therapeutic Lu-177-DOTA- girentuximab will be&#xD;
      administered the following week. In the absence of disease progression and after recovery&#xD;
      from toxicity, patients may be retreated no sooner than 12 weeks after the prior treatment&#xD;
      with a dose of no more than 75% of the previous dose, for a total of not more than three&#xD;
      treatments. Only patients who have normal pharmacokinetics on the preceding diagnostic&#xD;
      In-111-girentuximab study (indicative of human antichimeric antibodies (HACA) negativity) are&#xD;
      eligible for retreatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation according to RECIST criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Progression free survival is defined as the time measured from the day of first administration of Lu-177-girentuximab to first progression or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>up to 14 weeks after last therapeutic infusion</time_frame>
    <description>Toxicity defined by NCI Common Terminology Criteria for Adverse Events (CTCAE v3.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Metastatic Clear Cell Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Lu-177-DOTA-girentuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in receive 10 mg of girentuximab coupled to DOTA and labeled with 65 mCi/m2 of Lu-177 if targeting of In-111-DOTA-girentuximab is observed in at least 1 lesion. Patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu-177-DOTA-girentuximab</intervention_name>
    <description>Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.&#xD;
Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments.</description>
    <arm_group_label>Lu-177-DOTA-girentuximab</arm_group_label>
    <other_name>Lu-177-DOTA-cG250</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients with proven advanced and progressive RCC of the clear cell type&#xD;
&#xD;
          -  Presence of RECIST v.1.1 evaluable lesions, all &lt; 5 cm&#xD;
&#xD;
          -  Performance status: Karnofsky &gt; 70 %&#xD;
&#xD;
          -  Laboratory values: • White blood cells (WBC) &gt; 3.5 x 109/l • Platelet count &gt; 150 x&#xD;
             109/l • Hemoglobin &gt; 6 mmol/l • Total bilirubin &lt; 2 x upper limit of normal (ULN) •&#xD;
             ASAT, ALAT &lt; 3 x ULN (&lt; 5 x ULN if liver metastases present) • MDRD ≥ 40 ml/min&#xD;
&#xD;
          -  Negative pregnancy test for women of childbearing potential (urine or serum)&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Known or suspected CNS metastases including leptomeningeal metastases. History or&#xD;
             clinical evidence of (CNS) metastases (unless they are previously-treated CNS&#xD;
             metastases and patients meet all 3 of the following criteria: are asymptomatic, have&#xD;
             had no evidence of active CNS metastases for ≥3 months prior to enrollment, and have&#xD;
             had no requirement for steroids or enzyme inducing anticonvulsants in the last 14&#xD;
             days)&#xD;
&#xD;
          -  Untreated hypercalcemia&#xD;
&#xD;
          -  Chemotherapy, external beam radiation, immunotherapy or angiogenesis inhibitors or&#xD;
             mTOR inhibitors within 4 weeks prior to study. Limited field external beam&#xD;
             radiotherapy to prevent pathological fractures is allowed , when unirradiated,&#xD;
             evaluable lesions elsewhere are present.&#xD;
&#xD;
          -  Cardiac disease with New York Heart Association classification of III or IV&#xD;
&#xD;
          -  Patients who are pregnant, nursing or of reproductive potential and are not practicing&#xD;
             an effective method of contraception&#xD;
&#xD;
          -  Any unrelated illness, e.g. active infection, inflammation, medical condition or&#xD;
             laboratory abnormalities, which in the judgment of the investigator will significantly&#xD;
             affect patients' clinical status&#xD;
&#xD;
          -  Life expectancy shorter than 4 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. J. Oyen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nuclear Medicine, Radboud University Medical Center Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. F. Mulders, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Radboud University Medical Center Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>November 29, 2013</study_first_submitted>
  <study_first_submitted_qc>November 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <last_update_submitted>August 12, 2015</last_update_submitted>
  <last_update_submitted_qc>August 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Renal Cell Carcinoma</keyword>
  <keyword>Clear Cell Renal Cell Carcinoma (ccRCC)</keyword>
  <keyword>Lutetium-177</keyword>
  <keyword>Lu-177</keyword>
  <keyword>girentuximab</keyword>
  <keyword>cG250</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

